University of California, San Francisco
35 Medical Center Way, 903A
Box 0665
San Francisco
California
94143
United States
Website: http://www.ucsf.edu/
38 articles with University of California, San Francisco
-
In a small study of 14 rectal cancer patients, researchers at Memorial Sloan Kettering Cancer Center published results where 100% of the 12 patients who completed treatment went into remission.
-
Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting.
-
San Francisco-based Terremoto Biosciences launched with $75 million in Series A financing from OrbiMed and Third Rock Ventures as it develops highly targeted, small-molecule medicines.
-
This week, two studies provided big insights into brain changes and specific genetic sites and risk factors for Alzheimer’s disease. For those and more, continue reading.
-
With the International Conference on Alzheimer’s and Parkinson’s Diseases still ongoing, there has been increased news about Alzheimer’s. Here’s a look at just a few of the latest stories.
-
Researchers have now identified 16 new genetic variants associated with severe COVID-19. For that and more research stories, continue reading.
-
Researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark. For that and more COVID-19 news, continue reading.
-
The cash came rolling in for four biopharma companies Thursday morning, with collective Series A rounds totaling more than $125 million.
-
Known as the Reproducibility Project: Cancer Biology, it spent eight years replicating experiments from high-impact cancer biology papers published between 2010 and 2012.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones including T helper cells for COVID-19, new gene found that could contribute to type 1 diabetes and more.
-
Researchers have published a study of a woman being called the "Esperanza patient," one of what researchers call "elite controllers," who seem to eradicate HIV naturally.
-
The 174,000 square-foot location will house a fully-equipped production plant to create its initial programs for Type 1 diabetes, a specific genetic cause of autism, galactosemia, and more.
-
The National Academy of Medicine tapped 100 new members to its prestigious organization that represents some of the brightest minds in health and medicines. Here are some of them.
-
The NIH revealed that bumetanide, a drug typically used as a diuretic, maybe a potential treatment for those genetically at risk for Alzheimer's. Know more about it here.
-
Retrotope cited data from its Phase II/III trial of RT001 in patients with infantile neuroaxonal dystrophy and reported on a natural history study of INAD patients’ disease onset and progression.
-
Researchers at UCSF believed that a more personalized, deep brain stimulation could be a key. While DBS isn’t new, the UCSF team’s approach in their recently released study was unique.
-
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.
-
The U.S. CDC issued new guidance for long COVID, and the NIH is figuring out how to deal with the disease, while Tonix Pharma plans to develop TNX-102 SL.
-
Cala Health and University of California, San Francisco Announce Partnership to Develop Next-Generation, Smart Neuromodulation Therapies
6/17/2021
Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced a partnership with University of California, San Francisco to develop non-invasive, individualized, peripheral nerve stimulation therapies that leverage Cala Health’s neuromodulation and data science platform technology.
-
Researchers at multiple companies and institutes are doggedly pursuing clinical programs so the virus can become little more than a hindrance in the future.